Aimaz Afrough, MD
Hematology · Dallas, TXNPI 1477964518
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,519 of the $16,850 with a category attached, or 62.4%. 25 manufacturers reported payments, led by Johnson & Johnson at 26.1% of the total. Reporting peaked in 2024 at $11,798 and has fallen 74.8% since, to $2,969 in 2025.
Across 113 payments — averaging $149.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- Sanofi$4K
- E.r. Squibb & Sons, L.L.C.$3K
- Pfizer$2K
- Janssen Scientific Affairs, LLC$2K
- Bristol Myers Squibb$332
- plus $1K from 19 others
Across 109 payments — averaging $12,200 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1M
- AbbVie$172K
- Regeneron$148K
What the payments were for
- Consulting fees$10,51962%
- Speaking & faculty fees$2,20013%
- Travel & lodging$220%
- Food & beverage$3,99924%
- Education$1101%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 12 | $4,401 |
| Sanofi | 5 | $3,760 |
| E.r. Squibb & Sons, L.L.C. | 8 | $2,658 |
| Pfizer | 17 | $2,405 |
| Janssen Scientific Affairs, LLC | 9 | $1,802 |
| Bristol Myers Squibb | 18 | $332 |
| Karyopharm Therapeutics Inc. | 3 | $221 |
| Sanofi-aventis U.S. LLC | 1 | $174 |
| AstraZeneca | 7 | $141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $133 |
| Beigene USA, Inc. | 1 | $125 |
| Lilly USA, LLC | 8 | $115 |
| Legend Biotech USA Inc. | 1 | $104 |
| Astrazeneca UK Limited | 1 | $96 |
| Incyte Corporation | 4 | $66 |
| Adaptive Biotechnologies Corporation | 1 | $56 |
| Jazz Pharmaceuticals Inc. | 3 | $49 |
| Agios Pharmaceuticals, Inc. | 3 | $45 |
| Regeneron | 1 | $37 |
| Daiichi Sankyo Inc. | 1 | $31 |
| Tempus AI, Inc | 2 | $29 |
| Rigel Pharmaceuticals, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Eurofins Viracor, LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,850 in reported general payments places this provider in the 75th percentile of 97 hematology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 89 | $1,658,336 |
| Lenalidomide | 119 | $1,544,300 |
| PomalystPomalidomide | 28 | $624,633 |
| EliquisApixaban | 29 | $21,837 |
| Entecavir | 15 | $5,839 |
| Acyclovir | 130 | $1,117 |
| ValacyclovirValacyclovir Hcl | 27 | $1,109 |
| Ondansetron Hcl | 45 | $786 |
| Dexamethasone | 67 | $763 |
| Gabapentin | 13 | $524 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 16 | $314 |
| Prochlorperazine Maleate | 19 | $211 |
| Pantoprazole Sodium | 14 | $143 |
| Potassium Chloride | 19 | $89 |
| Tramadol Hcl | 11 | $49 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $332 | $1,658,33689 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $2,658 | $624,63328 claims |
| PfizerEliquis | $2,405 | $21,83729 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $17 | $1,117130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 97 hematology providers in Texas.
Other hematology in Dallas
- Taha BatDallas$81K
- Ankit KansagraDallas$41K
- Mingyi ChenDallas$37K
- Arthur FrankelDallas$31K
- Kirthi KumarDallas$19K
- Alecia NeroDallas$10K
- Jean Antoine RibeilDallas$5K
- Ameen SalahudeenDallas$4K
- Natalie BavliDallas$822
- Miguel EscobarHouston$767K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.